AstraZeneca's lung cancer trial has finished enrollment; results are expected in 2027.
AstraZeneca's PACIFIC-9 Phase 3 trial, evaluating durvalumab with monalizumab or oleclumab for unresectable Stage III NSCLC, has completed enrollment. Results are now expected in the first half of 2027, delayed from the second half of 2026. Monalizumab is developed by Innate Pharma in collaboration with AstraZeneca.
How this was made
The 30-second read
Why it matters
The timing shift may temper short‑term enthusiasm for both companies, but does not alter the long‑term potential of the therapy.
Market read
Trial readout delay is a material update for investors in oncology biotech, affecting AZN and IPHA valuations.
What to watch
Potential for additional data collection may improve eventual efficacy readout, offsetting timing concerns.
Background
AstraZeneca leads the PACIFIC-9 Phase 3 trial of durvalumab with Innate Pharma's antibodies. Enrollment is complete, but the high‑level data readout has been pushed to early 2027.
Ticker impact
AstraZeneca updated the PACIFIC-9 Phase 3 trial readout to H1 2027, delaying expected data.
likely modest downside as investors price in a later data readout
Trial timeline shifts are material for biotech stocks but the impact is gradual and depends on future data.
Innate Pharma announced the trial timing change for its partner AstraZeneca, confirming enrollment is complete.
potential slight pressure as the market adjusts expectations for monalizumab data
The company’s value is tied to the upcoming readout; a later date reduces near‑term upside.
Market effects
Oncology trial timelines may cause broader caution in biotech sector.
European biotech listings could see modest re‑rating.
Limited to investors tracking cancer immunotherapy pipelines.
Counterpoint
The delay could be seen as a positive sign that the trial is proceeding without safety setbacks.
Key entities
- CompanyAstraZeneca
Global pharmaceutical firm leading the trial.
- CompanyInnate Pharma
Biotech partner developing monalizumab and oleclumab.
